secwatch.observer — SEC 8-K summary
======================================

Issuer:     Maze Therapeutics, Inc. (MAZE)
CIK:        0001842295
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0000950170-25-071357
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Maze Therapeutics Q1 net loss $32.8M; cash $294.4M; MZE829/MZE782 milestones reiterated
--------------------------------------------------------------------------------

- Cash and cash equivalents: $294.4M at March 31, 2025, up from $196.8M at Dec 31, 2024; runway into H2 2027.
- Net loss of $32.8M for Q1 2025, vs $32.5M in Q1 2024; R&D expenses $27.6M (up from $21.9M).
- MZE829 Phase 2 HORIZON trial enrolling APOL1 kidney disease patients; initial proof-of-concept data expected Q1 2026.
- MZE782 Phase 1 healthy volunteer trial ongoing; initial biomarker data expected Q3 2025.
- Cash increase largely from IPO proceeds; no revenue reported (clinical-stage biotech).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842295/000095017025071357/0000950170-25-071357-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842295/000095017025071357/maze-20250514.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-071357

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer